Over the last decade, interest in treatment of ischemic stroke has increased significantly. Perhaps the single most important feature of attempts to improve the outcome of stroke patients has been that the interventions be applied within the very early hours of stroke symptoms. This has spawned efforts to understand the vascular and neuronal responses to cerebral artery reperfusion experimentally. Important prospective clinical studies of thrombolysis in acute ischemic stroke have been completed, and large placebo-controlled, symptom-based studies are now underway worldwide. Here, we consider the central features of those studies, their experimental basis, and the future importance of adjunctive therapies to recanalization in focal brain ischemia acutely. Risks and benefits are discussed. This collection benefits from the opinions of experts and workers in this rapidly evolving and exciting field.
Sprache
Verlagsort
Verlagsgruppe
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Research
Illustrationen
36
36 s/w Abbildungen
XIV, 334 p. 36 illus.
Maße
Höhe: 235 mm
Breite: 155 mm
Dicke: 20 mm
Gewicht
ISBN-13
978-3-540-56442-3 (9783540564423)
DOI
10.1007/978-3-642-78061-5
Schweitzer Klassifikation
Background to Thrombolytic Therapy in Acute Ischemic Stroke.- Therapy for Acute Ischemic Stroke: Clinical Needs and Statistical Burdens.- Clinical Outcome of Acute Ischemic Stroke: Prospective Angiographic Studies.- The Ischemic Penumbra: Usefulness of PET.- Thrombolytic Agents: Lessons for Their Use in Acute Stroke from Myocardial Infarction Experience.- Pathogenesis of Secondary Brain Hemorrhage After Ischemia: Lessons from Animal Models . and a few from man, too!.- Clinical Trials of Fibrinolytic Agents in Carotid Territory Cerebral Ischemia.- Symptom-Based Trials of Intravenous rt-PA in Acute Stroke.- A Safety and Efficacy Study of Intravenous rt-PA in Patients with Acute Stroke.- Recanalization, Infarct Volume, Cerebral Hemorrhage, and Clinical Outcome After Intravenous Recombinant Tissue Plasminogen Activator and Heparin in Acute Carotid Territory Stroke.- Intravenous Tissue Plasminogen Activator in Acute Thromboembolic Stroke: A Placebo-Controlled, Double-Blind Trial.- The European Cooperative Acute Stroke Study (ECASS).- On the Estimation of the Sample Size for the ECASS Study.- Australian Streptokinase Trial (ASK).- Thrombolytic and Antithrombotic Therapy in Acute Ischemic Stroke. Multicenter Acute Stroke Trial - Italy (MAST-I).- Discussion Summary: Clinical Trials in Progress.- Other Applications of Fibrinolytic Agents in the Central Nervous System.- Acute Central Retinal Artery Occlusion and the Role of Thrombolysis.- Current Status of Fibrinolysis for the Rapid Dissolution of Subarachnoid and Intraventricular Clot.- Discussion Summary: Other Applications of Fibrinolytic Agents in the Central Nervous System.- Insights into the Pathogenesis of Cerebral Ischemia Relevant to Fibrinolysis.- Deterioration of Acute Stroke.- Early Spontaneous Recanalization ofThromboembolic Stroke.- Spectacular Shrinking Deficits in Acute Ischemic Stroke.- The Significance of Various Factors Associated with Hemorrhagic Transformation in Patients Treated with Recombinant Tissue Plasminogen Activator for Acute Stroke.- Thrombolysis: Stroke Subtype and Embolus Type.- The Prognostic Value of Collateral Blood Flow in Acute Middle Cerebral Artery Occlusion.- Morphological Evidence of Progressive Microvascular Impairment in Middle Cerebral Artery Occlusion-Reperfusion.- Discussion Summary: Insights into the Pathogenesis of Cerebral Ischemia Relevant to Fibrinolysis.- Diagnosis and Assessment of Outcomes in Acute Cerebral Ischemia.- The Relevance of CT Scanning and Angiography for Patients with Acute Stroke Treated with Recombinant Tissue Plasminogen Activator.- Recanalization of the Embolically Occluded Middle Cerebral Artery in Acute Stroke Patients: Noninvasive Assessment and Outcome.- Potential Role of Magnetic Resonance Imaging in Selecting Patients for Thrombolytic Therapy.- The Role of SPECT in Acute Stroke Thrombolysis.- Clinical and Brain Hemodynamic Evaluations of Thrombolytic Therapy in Acute Ischemic Stroke: SPECT Study.- The Relevance of Neurological and Functional Outcome Scales for Acute Stroke Trials.- Discussion Summary: Diagnosis and Assessment of Outcomes in Acute Cerebral Ischemia.- Ancillary Therapy for Cerebrovascular Reperfusion.- Neuronal Protection and Recanalization Strategies: Is More Better?.- Strategies Which Decrease Post-Reperfusion Lipid Peroxidation.- Anti-PMN Leukocyte Strategies and Their Application to Focal Cerebral Ischemia.- Von Willebrand Factor as a Target for Antithrombotic Intervention.- Neuronal Protection: Is There a Role for Gangliosides or Ca2+-Channel Blockers?.- Discussion Summary: Ancillary Therapyfor Cerebrovascular Reperfusion.- Open Communications.- A Meta-Analysis of All Published Data on the Use of Thrombolytic Therapy to Treat Acute Ischemic Stroke.- Causes of Delayed Treatment of Stroke Patients Enrolled in t-PA Protocols.- A Demming Approach to Recruiting: The National Institute of Neurological Disease and Stroke (NINDS) t-PA Stroke Trial Experience.- Local Intra-arterial Fibrinolytic Therapy Within the Cerebral Arteries: Effectiveness of rt-PA Concerning Recanalization Rate and Time.- Relation of Thrombolytic Reperfusion and of Collateral Circulation to Outcome in Patients Suffering Cerebral Main Artery Occlusion.- Factors Related to Intracranial Hematoma Formation in Patients Receiving t-PA for Acute Ischemic Stroke.- Transcranial Doppler Sonographic (TCD) Monitoring of Basilar Artery Thrombolysis.- HMPAO SPECT Measures Reperfusion After Thrombolytic Therapy in Acute Stroke.- A Cell Culture Model of Reperfusion Injury: Neutrophil-Mediated Brain Endothelial Cytotoxicity.- Modification of Brain Ischemia Due to Embolic Stroke by Tissue-Type Plasminogen Activator With and Without Heparin in a Rabbit Model.- Reduction of Infarct Volume and Mortality by Thrombolysis with rt-PA in an Embolic Stroke Model.- Discussion Summary: Open Communications.- Clinical Trial Development.- Clinical Trials Sponsored by Companies Versus the NIH.- Blindness and Thrombolysis.
